Ausgabe 2/2017
Inhalt (22 Artikel)
Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity
Júlia Coelho França Quintanilha, Vanessa Marcilio de Sousa, Marília Berlofa Visacri, Laís Sampaio Amaral, Roseane Maria Maia Santos, Tomás Zambrano, Luis Antonio Salazar, Patricia Moriel
Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells
Li Xu, Yingya Fu, Youlun Li, Xiaoli Han
Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma
Kaiming Ren, Ran Xu, Jingshan Huang, Jungang Zhao, Wenjun Shi
Genetic variability in the regulation of the expression cluster of MDR genes in patients with breast cancer
Matvey M. Tsyganov, Maxim B. Freidin, Marina K. Ibragimova, Irina V. Deryusheva, Polina V. Kazantseva, Elena M. Slonimskaya, Nadezhda V. Cherdyntseva, Nikolai V. Litviakov
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
Howard A. Burris III, C. D. Kurkjian, L. Hart, S. Pant, P. B. Murphy, S. F. Jones, R. Neuwirth, C. G. Patel, F. Zohren, J. R. Infante
JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin
Mingning Qiu, Longzhi Ke, Sai Zhang, Xin Zeng, Zesong Fang, Jianjun Liu
Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity
Chengcheng Liu, Laura J. Janke, Jun J. Yang, William E. Evans, John D. Schuetz, Mary V. Relling
Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes
Dale R. Miles, Steven A. Lacy, David R. Wada, Steve Milwee, Yifah Yaron, Linh T. Nguyen
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
Makoto Ueno, Chung Pin Li, Masafumi Ikeda, Hiroshi Ishii, Nobumasa Mizuno, Taketo Yamaguchi, Tatsuya Ioka, Do Youn Oh, Wataru Ichikawa, Takuji Okusaka, Yutaka Matsuyama, Daichi Arai, Li Tzong Chen, Young Suk Park, Junji Furuse
Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague–Dawley rats
Richard A. Forsgård, Vannina G. Marrachelli, Katri Korpela, Rafael Frias, Maria Carmen Collado, Riitta Korpela, Daniel Monleon, Thomas Spillmann, Pia Österlund
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer
Kotoe Takayoshi, Hitoshi Kusaba, Masato Uenomachi, Kenji Mitsugi, Chinatsu Makiyama, Akitaka Makiyama, Keita Uchino, Tsuyoshi Shirakawa, Yoshihiro Shibata, Yudai Shinohara, Kyoko Inadomi, Kenji Tsuchihashi, Shuji Arita, Hiroshi Ariyama, Taito Esaki, Koichi Akashi, Eishi Baba
Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
Ida Netterberg, Elisabet I. Nielsen, Lena E. Friberg, Mats O. Karlsson
A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)
Tadahiro Shoji, Eriko Takatori, Hideo Omi, Masahiro Kagabu, Tatsuya Honda, Masayuki Futagami, Yoshihito Yokoyama, Michiko Kaiho, Hideki Tokunaga, Takeo Otsuki, Tadao Takano, Nobuo Yaegashi, Takanobu Kojimahara, Tsuyoshi Ohta, Satoru Nagase, Shu Soeda, Takafumi Watanebe, Hiroshi Nishiyama, Toru Sugiyama
Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patients
Wan-Su Park, Gab-jin Park, Seunghoon Han, Sooho Ban, Moon-Young Park, San-ho Kim, Seon-Myung Kim, Yong-Chul Kim, Hyung Sik Kim, Young G. Shin, Dong-Seok Yim
Does “OPTINAB” strategy (“stop-and-go”) work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel–gemcitabine?
Valerie Relias, Antonia Maloney, Melissa H. Smith, Muhammad Wasif Saif
Eribulin shows high concentration and long retention in xenograft tumor tissues
Michiko Sugawara, Krista Condon, Earvin Liang, Christopher DesJardins, Edgar Schuck, Kazutomi Kusano, W. George Lai
Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring
Dhanusha Sabanathan, Alison Zhang, Peter Fox, Sally Coulter, Val Gebski, Bavanthi Balakrishnar, Mathew Chan, Christopher Liddle, Howard Gurney
Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1)
Xiaofei Yan, Jian Zhao, Rui Zhang
Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience
Alberto A. Mendivil, Mark A. Rettenmaier, Lisa N. Abaid, John V. Brown III, Kristina M. Mori, Katrina L. Lopez, Bram H. Goldstein
Hinokitiol suppresses cancer stemness and oncogenicity in glioma stem cells by Nrf2 regulation
Wen-Chen Ouyang, Yi-Wen Liao, Pei-Ni Chen, Kai-Hsi Lu, Cheng-Chia Yu, Pei-Ling Hsieh
Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy
M. K. Boss, M. W. Dewhirst, R. S. Sampaio, A. Bennett, A. Tovmasyan, K. G. Berman, A. W. Beaven, D. A. Rizzieri, I. Batinic-Haberle, M. L. Hauck, I. Spasojevic
Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients
Jürgen Burhenne, Lu Liu, Christoph E. Heilig, Andreas D. Meid, Margarete Leisen, Thomas Schmitt, Bernd Kasper, Walter E. Haefeli, Gerd Mikus, Gerlinde Egerer